NewsRoom Articles - Page 98 of 154 - PsychedelicNewsWire (PNW)

WednesdayMay 12, 2021 12:15 pm

At-Home Genetics Test May Help Detect Possible Psychedelic Therapy Risks

Psychedelics are making a comeback in Western society, having started the journey to mainstream a few years ago. This renaissance has brought with it a lot of new discoveries, many of which are useful for the mental health field. As mental health disorders increase at a rather alarming rate, the research on various psychedelics as potential alternative treatments has been welcomed by many, especially those in the psychedelic field and those who would like to indulge in psychedelics as well as users of these substances. However, as with any other drug, psychedelics carry some risk, and with more jurisdictions beginning…

TuesdayMay 11, 2021 2:30 pm

Minnesota Clinic Provides Model for Therapeutic Use of Psychedelics

Since selective serotonin reuptake inhibitor antidepressants (“SSRIs”) were introduced in the late ‘80s, little has changed in how different mental health conditions are treated. The co-founder of the Institute for Integrative Therapies (“IIT”) Manoj Doss notes that there haven’t been many breakthroughs in the psychiatry field in the recent past. Doss, who is certified in both general and occupational medicine, asserts that a need exists to re-examine how mental illnesses are treated, adding that the treatments used need to be more effective. This is why he and his co-founder, Kyle Keller, are trying to approach the treatment of various mental…

TuesdayMay 11, 2021 1:17 pm

Business Booming in April: Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Lands Tolling Agreement to Extract CBD from 500 Kg Hemp Biomass

CBD-infused products market is expected to grow 48.1% annually to reach $165.7 billion by 2027 Pure Extracts Technologies’ subsidiary recently began production of goods expected to generate approximately $950,000 in revenue New tolling agreement is for extraction of 80-85% pure CBD distillate from an initial 500 kilograms (~1,102 pounds) of hemp biomass Any industry forecast for double-digit growth is one worth keeping an eye on. When experts are calling for mid-double-digit annual market growth, like that of CBD-infused products, it’s worth a head turn and a stare. Meticulous Research this month forecast this market to experience compound annual growth of…

MondayMay 10, 2021 12:10 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Looks to New Senior Management with Expertise in Development, Clinical Capabilities

Company committed to building presence in U.S. and Europe to advance mission of improving mental health care New appointments will strengthen Cybin’s development and clinical operations globally, solidify position within the industry New leaders bring broad experience, deep insight to their new roles Cybin (NEO: CYBN) (OTCQB: CLXPF), a leading biotech company focused on progressing psychedelic therapeutics, recently made key senior-management changes designed to provide the company with added insight and expertise in the expansion of its development and clinical operations in the United States and Europe (https://ibn.fm/FsF0L). The appointments, which are effective immediately, call for Alexander Belser, PhD, to…

MondayMay 10, 2021 11:00 am

Researchers Have Designed a Sensor to Detect Psychedelics That Aren’t Hallucinogenic

Researchers have come up with a way to determine if a molecule can induce hallucinations, without testing it on animals or people. Evidence from prior research has suggested that psychedelic compounds could be used to manage psychiatric conditions such as PTSD. Scientists are therefore looking for ways to retain the beneficial properties of psychedelic drugs but get rid of their hallucinogenic side effects, which can make treatment more challenging. At the moment, it isn’t possible to forecast whether a drug can give rise to hallucinations before researchers carry out tests on people or animals. University of California chemical neuroscientist David…

FridayMay 07, 2021 2:00 pm

How Psilocybin Testers Identify Award-Winning Magic Mushrooms

Last weekend, enthusiasts of plant medicine took part in the first-ever Psilocybin Cup. The event, which was organized by an incubation lab and consulting firm in Oakland, California, called Oakland Hyphae, had growers of magic mushrooms submit their mushrooms to the lab. This event comes after the City Council of Oakland decriminalized psychoactive plants and fungi, which include psilocybin mushrooms, in 2019. Researchers tested the samples that had been submitted for the cup by more than 50 cultivators in order to determine how much psilocin and psilocybin were in each mushroom. The two ingredients are hallucinogenic compounds found in psilocybin…

FridayMay 07, 2021 1:46 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Investigates Alleviating Neurological Disorders with Psychedelics

Tryp Therapeutics is a pharmaceutical developer working to produce novel bioscience solutions, including a synthetic psychedelic drug candidate for treating some chronic pain and eating disorders Tryp CEO Greg McKee appeared on the Entrepreneur Magazine podcast “Action and Ambition” earlier this month to discuss lessons learned on his road to success and to highlight the company’s purpose in developing treatments for helping people be more whole Psychedelic drug therapies have been developing a growing fanbase, highlighted by California state Sen. Scott Wiener’s legislation this year seeking to decriminalize hallucinogenics McKee noted that many military personnel are using psychedelics in an…

ThursdayMay 06, 2021 2:00 pm

Study Finds Complex Relationship Between Creativity, Psilocybin

A new study has discovered that individuals under the influence of psilocybin tend to have more original and profound thoughts. However, cognitive tests on creative ability conducted have shown that they score lower in the short term, with findings indicating that psilocybin, which is the active ingredient in magic mushrooms, improves an individual’s creative ability in the long term. The research gathered proton magnetic resonance spectroscopy and functional magnetic resonance imaging data. which offered new insights into the basic neurobiological mechanisms linked to creativity. Maastricht University PhD candidate Natasha Mason, who also happens to be the lead researcher of the…

WednesdayMay 05, 2021 2:00 pm

Psychedelic Experience Not Necessary for Individuals to Benefit from Psilocybin’s Antidepressant Effects

Researchers from the University of Maryland School of Medicine have demonstrated that psilocybin can act an as antidepressant even if a psychedelic experience doesn’t occur. Psilocybin is the active ingredient found in magic mushrooms. The findings propose that psychedelic substances work in different ways within the brain. It is therefore possible to confer the drug’s antidepressant benefits without the need of therapy sessions. A variety of psilocybin that has less of or no psychedelic effect could help lower the cost of therapy and ease restrictions on individuals who receive therapy, which would make the beneficial effects of psilocybin better available…

WednesdayMay 05, 2021 12:04 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Signs Drug-Development Agreement, One Step Closer to Effective Psychiatric Disorder Treatment

Agreement calls for Cybin, Catalent to work together to develop novel therapy for treatment-resistant psychiatric disorders Cybin looking to identify fast-acting, shorter-duration formulations of CYB003 Delivering CYB003 through Catalent ODT could provide significant benefits Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has inked a drug-development agreement with Catalent Inc. (NYSE: CTLT), a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products (https://ibn.fm/nQdpg). The agreement, which is scheduled to start this month, calls for the two companies to work together to potentially…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000